Reading Time: < 1 minute
The partnering process continues for Respiratorius, which recently released the report for the third quarter. The US patent has been approved and the focus is now on refining the VAL001 project, with a particular focus on the regulatory aspects.
– We have a clear strategy to clarify and strengthen the company’s values as well as a clear regulatory strategy, says Johan Drott to BioStock.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/11/respiratorius-ceo-we-continue-to-reduce-risk-in-the-project/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
